Nasdaq · CIK 0001404644
NGNE Neurogene Inc.
Insider trading from SEC Form 4. Last filing 11 d ago. Close $26.40 on Oct 9, 2026, +61% from the 52-week low and -38% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
NGNEOct 9, 2026 · close 26.40
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Neurogene Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 24Weak | Christine Mikail Cvijic President and CFO sell | $55k 2,558 shares | -2% | +192% from low-38% from high | |
| 10Weak | Julie Jordan Chief Medical Officer sell | $18k 828 shares | -6% | +192% from low-38% from high | |
| 28Weak | Rachel McMinn Chief Executive Officer sell | $74k 3,352 shares | -0% | +192% from low-38% from high | |
| 26Weak | Stuart Cobb Chief Scientific Officer sell | $141k 6,797 shares | -18% | +193% from low-37% from high | |
| 26Weak | Christine Mikail Cvijic President and CFO sell | $84k 4,045 shares | -4% | +193% from low-37% from high | |
| 20Weak | Christine Mikail Cvijic President and CFO sell | $121k 4,800 shares | -4% | +220% from low-32% from high | |
| 10Weak | Stuart Cobb Chief Scientific Officer sell | $103k 6,797 shares | -25% | +107% from low-79% from high | |
| 10Weak | Christine Mikail Cvijic President and CFO sell | $76k 4,501 shares | -6% | +12% from low-77% from high | |
| 47Moderate | Samsara BioCapital GP, LLC owner buy | $1.3M 48,770 shares | +3% | - | |
| 61Notable | Christine Mikail Cvijic President and CFO buy | $491k 24,000 shares | +45% | - | |
| 65Notable | Rachel McMinn Chief Executive Officer buy | $969k 47,500 shares | +4% | - |
Transactions
The last 43 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | Rachel McMinn Chief Executive Officer | MOption exercise Common Stock | +756 | $25.32 | $19k | 1,345,063 | 11 d ago |
| Sep 22, 2026 | Rachel McMinn Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative | -756 | $0.00 | $0 | 0 | 11 d ago |
| Mar 26, 2026 | Christine Mikail Cvijic President and CFO | SOpen-market sale Common Stock10b5-1 | -2,558 | $21.62 | $55k | 103,240 | Mar 30, 2026 |
| Mar 26, 2026 | Julie Jordan Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -828 | $21.89 | $18k | 12,472 | Mar 30, 2026 |
| Mar 26, 2026 | Rachel McMinn Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -3,352 | $22.07 | $74k | 1,344,307 | Mar 30, 2026 |
| Mar 13, 2026 | Christine Mikail Cvijic President and CFO | SOpen-market sale Common Stock10b5-1 | -2,387 | $20.42 | $49k | 107,456 | Mar 17, 2026 |
| Mar 13, 2026 | Stuart Cobb Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -3,991 | $20.41 | $81k | 33,303 | Mar 17, 2026 |
| Mar 13, 2026 | Stuart Cobb Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -2,658 | $21.34 | $57k | 30,645 | Mar 17, 2026 |
| Mar 13, 2026 | Christine Mikail Cvijic President and CFO | SOpen-market sale Common Stock10b5-1 | -1,395 | $21.25 | $30k | 106,061 | Mar 17, 2026 |
| Mar 13, 2026 | Stuart Cobb Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -148 | $22.08 | $3,268 | 30,497 | Mar 17, 2026 |
| Mar 13, 2026 | Christine Mikail Cvijic President and CFO | SOpen-market sale Common Stock10b5-1 | -263 | $22.02 | $5,791 | 105,798 | Mar 17, 2026 |
| Feb 27, 2026 | Christine Mikail Cvijic President and CFO | SOpen-market sale Common Stock10b5-1 | -4,800 | $25.11 | $121k | 109,843 | Mar 3, 2026 |
| Feb 20, 2026 | Rohan Palekar director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +12,050 | $0.00 | $0 | 12,050 | Feb 24, 2026 |
| Feb 20, 2026 | Keith Woods director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +12,050 | $0.00 | $0 | 12,050 | Feb 24, 2026 |
| Feb 20, 2026 | Sarah B. Noonberg director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +12,050 | $0.00 | $0 | 12,050 | Feb 24, 2026 |
| Feb 20, 2026 | Rachel McMinn Chief Executive Officer | AGrant or award Common Stock | +25,900 | $0.00 | $0 | 1,347,659 | Feb 24, 2026 |
| Feb 20, 2026 | Julie Jordan Chief Medical Officer | AGrant or award Common Stock | +4,900 | $0.00 | $0 | 13,300 | Feb 24, 2026 |
| Feb 20, 2026 | Christine Mikail Cvijic President and CFO | AGrant or award Common Stock | +22,000 | $0.00 | $0 | 114,643 | Feb 24, 2026 |
| Feb 20, 2026 | Stuart Cobb Chief Scientific Officer | AGrant or award Common Stock | +16,500 | $0.00 | $0 | 37,294 | Feb 24, 2026 |
| Feb 20, 2026 | Robert Baffi director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +12,050 | $0.00 | $0 | 12,050 | Feb 24, 2026 |
| Feb 20, 2026 | Cory S. Freedland director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +12,050 | $0.00 | $0 | 12,050 | Feb 24, 2026 |
| Feb 20, 2026 | Julie Jordan Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +29,600 | $0.00 | $0 | 29,600 | Feb 24, 2026 |
| Feb 20, 2026 | Christine Mikail Cvijic President and CFO | AGrant or award Stock Option (Right to Buy)derivative | +131,900 | $0.00 | $0 | 131,900 | Feb 24, 2026 |
| Feb 20, 2026 | Rachel McMinn Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +155,100 | $0.00 | $0 | 155,100 | Feb 24, 2026 |
| Jun 12, 2025 | Robert Baffi director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +12,050 | $0.00 | $0 | 12,050 | Jun 13, 2025 |
| Jun 12, 2025 | Cory S. Freedland director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +12,050 | $0.00 | $0 | 12,050 | Jun 13, 2025 |
| Jun 12, 2025 | Sarah B. Noonberg director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +12,050 | $0.00 | $0 | 12,050 | Jun 13, 2025 |
| Jun 12, 2025 | Rohan Palekar director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +12,050 | $0.00 | $0 | 12,050 | Jun 13, 2025 |
| Jun 12, 2025 | Robert Keith Woods director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +12,050 | $0.00 | $0 | 12,050 | Jun 13, 2025 |
| May 14, 2025 | Stuart Cobb Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -6,797 | $15.15 | $103k | 20,794 | May 15, 2025 |
| Mar 26, 2025 | Stuart Cobb Chief Scientific Officer | AGrant or award Common Stock | +7,200 | $0.00 | $0 | 27,591 | Mar 28, 2025 |
| Mar 26, 2025 | Julie Jordan Chief Medical Officer | AGrant or award Common Stock | +8,400 | $0.00 | $0 | 8,400 | Mar 28, 2025 |
| Mar 26, 2025 | Christine Mikail Cvijic President and CFO | AGrant or award Common Stock | +20,300 | $0.00 | $0 | 92,643 | Mar 28, 2025 |
| Mar 26, 2025 | Christine Mikail Cvijic President and CFO | AGrant or award Employee Stock Option (Right to buy)derivative | +122,000 | $0.00 | $0 | 122,000 | Mar 28, 2025 |
| Mar 26, 2025 | Stuart Cobb Chief Scientific Officer | AGrant or award Employee Stock Option (Right to buy)derivative | +42,900 | $0.00 | $0 | 42,900 | Mar 28, 2025 |
| Mar 26, 2025 | Julie Jordan Chief Medical Officer | AGrant or award Employee Stock Option (Right to buy)derivative | +50,300 | $0.00 | $0 | 50,300 | Mar 28, 2025 |
| Mar 13, 2025 | Christine Mikail Cvijic President and CFO | SOpen-market sale Common Stock10b5-1 | -4,501 | $16.94 | $76k | 72,343 | Mar 17, 2025 |
| Nov 26, 2024 | Samsara BioCapital GP, LLC owner | POpen-market purchase Common Stockindirect: By Samsara BioCapital, L.P. | +20,748 | $24.91 | $517k | 1,689,105 | Nov 27, 2024 |
| Nov 26, 2024 | Samsara BioCapital GP, LLC owner | POpen-market purchase Common Stockindirect: By Samsara BioCapital, L.P. | +10,803 | $26.01 | $281k | 1,699,908 | Nov 27, 2024 |
| Nov 26, 2024 | Samsara BioCapital GP, LLC owner | POpen-market purchase Common Stockindirect: By Samsara BioCapital, L.P. | +15,219 | $26.73 | $407k | 1,715,127 | Nov 27, 2024 |
| Nov 26, 2024 | Samsara BioCapital GP, LLC owner | POpen-market purchase Common Stockindirect: By Samsara BioCapital, L.P. | +2,000 | $27.50 | $55k | 1,717,127 | Nov 27, 2024 |
| Nov 22, 2024 | Christine Mikail Cvijic President and CFO | POpen-market purchase Common Stock | +24,000 | $20.48 | $491k | 76,844 | Nov 25, 2024 |
| Nov 22, 2024 | Rachel McMinn Chief Executive Officer | POpen-market purchase Common Stock | +47,500 | $20.40 | $969k | 1,297,859 | Nov 25, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Robert Baffidirector
- Stuart CobbChief Scientific Officer
- Christine Mikail CvijicPresident and CFO
- Cory S. Freedlanddirector
- Julie JordanChief Medical Officer
- Rachel McMinnChief Executive Officer
- Sarah B. Noonbergofficer, director
- Rohan Palekarceo, officer, director
- Samsara BioCapital GP, LLCowner
- Keith Woodscoo, officer, director
- Robert Keith Woodsdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.